Home › Marginal Zone Lymphoma
Pag-aaral pangklinika para sa Marginal Zone Lymphoma na nagre-recruit sa U.S.
55 pag-aaral para sa Marginal Zone Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Durham, NC12 pag-aaral
- New York City, NY11 pag-aaral
- Milwaukee, WI9 pag-aaral
- Seattle, WA9 pag-aaral
- Boston, MA9 pag-aaral
- Baldwin Park, CA9 pag-aaral
- Columbus, OH8 pag-aaral
- Edison, NJ8 pag-aaral
- Houston, TX8 pag-aaral
- Rochester, MN8 pag-aaral
- Denver, CO7 pag-aaral
- Miami, FL7 pag-aaral
- Salt Lake City, UT6 pag-aaral
- Jacksonville, FL6 pag-aaral
- Nashville, TN6 pag-aaral
- St. Louis, MO6 pag-aaral
- Dallas, TX5 pag-aaral
- Portland, OR5 pag-aaral
- Queens, NY5 pag-aaral
- Greenburgh, NY5 pag-aaral
- Chicago, IL5 pag-aaral
- Washington, DC5 pag-aaral
- Cleveland, OH5 pag-aaral
- Atlanta, GA5 pag-aaral
- Cincinnati, OH4 pag-aaral
- Buffalo, NY4 pag-aaral
- New Rochelle, NY4 pag-aaral
- Staten Island, NY4 pag-aaral
- Los Angeles, CA4 pag-aaral
- Tampa, FL4 pag-aaral
- Minneapolis, MN4 pag-aaral
- Philadelphia, PA4 pag-aaral
- Providence, RI3 pag-aaral
- Mountain View, CA3 pag-aaral
- East Norwalk, CT3 pag-aaral
- Richmond, VA3 pag-aaral
- Scottsdale, AZ3 pag-aaral
- Cedar Rapids, IA3 pag-aaral
- New Haven, CT3 pag-aaral
- Ann Arbor, MI3 pag-aaral
Ayos sa estado
- Arizona5 pag-aaral
- California18 pag-aaral
- Colorado8 pag-aaral
- Connecticut4 pag-aaral
- Florida15 pag-aaral
- Georgia6 pag-aaral
- Illinois6 pag-aaral
- Iowa4 pag-aaral
- Kansas3 pag-aaral
- Maryland6 pag-aaral
- Massachusetts12 pag-aaral
- Michigan5 pag-aaral
- Minnesota12 pag-aaral
- Missouri6 pag-aaral
- New Jersey9 pag-aaral
- New York16 pag-aaral
- North Carolina14 pag-aaral
- Ohio13 pag-aaral
- Oregon5 pag-aaral
- Pennsylvania5 pag-aaral
- Rhode Island3 pag-aaral
- Tennessee7 pag-aaral
- Texas12 pag-aaral
- Utah6 pag-aaral
- Virginia4 pag-aaral
- Washington10 pag-aaral
- Wisconsin10 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07583810Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06350318A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT00923507Epco, Zanu, Ritux for R/R FL or MZL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06563596Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05296070Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07225439A Study of ARC-02 in B-cell NHL
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT07691606Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT04792502A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT06149286AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT06340737HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT06792825LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Nagre-recruitPhase 1
Edad 18 hanggang 81 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT05990465Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06708897A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 24, 2026 · NCT07121946Allo HSCT Using RIC and PTCy for Hematological Diseases
Nagre-recruitPhase 2
Hanggang edad 75 · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT05805605A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT06860880Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT06905509Registry of Older Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 65 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT01137825Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Nagre-recruitPhase 2
Hanggang edad 60 · Lahat ng kasarian · Na-update Hun 25, 2026 · NCT03314974Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.